Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.
Bone marrow angiogenesis is increased in non-Hodgkin lymphomas (NHL). Compounds affecting extracellular matrix (ECM) may modify angiogenesis. Here we investigated ECM regulators in 48 unselected NHL patients compared with 35 controls. Untreated patients had elevated (P < 0.05) serum matrix metalloproteinase (MMP) 9 and tissue inhibitor of metalloproteinase (TIMP) 1, while MMP-2, TIMP-2 and syndecan-1 were not significantly different from controls. MMP-9 mRNA was significantly up-regulated in blood mononuclear cells, while mRNA expressions of the other ECM regulators were unaltered. We found strong correlations between mRNA expressions of both vascular endothelial growth factor and fibroblast growth factor 2, and MMP-9, TIMP-1 and TIMP-2. After therapy, serum MMP-2 increased while MMP-9 decreased (P < 0.05), the others being unchanged. Several compounds affecting ECM may be involved in angiogenic activity in NHL.
Department of Haematology, Oslo University Hospital Ullevål, Oslo, Norway. Helene.Negaard@medisin.uio.no
Helene F S
HF
Negaard
Katja
K
Svennevig
Svein Olav
SO
Kolset
Nina
N
Iversen
Inger Marie Bowitz
IM
Lothe
Bjørn
B
Østenstad
Per Morten
PM
Sandset
Per Ole
PO
Iversen
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005109:Extracellular Matrix / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000097:blood / Q000235:genetics / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000097:blood* / Q000235:genetics / Q000378:metabolism; D008875:Middle Aged; D053668:Syndecan-1 / Q000097:blood / Q000235:genetics / Q000378:metabolism; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood / Q000235:genetics / Q000378:metabolism; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000097:blood / Q000235:genetics / Q000378:metabolism; D019714:Tissue Inhibitor of Metalloproteinases / Q000097:blood* / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome
D053668:Syndecan-1; D019715:Tissue Inhibitor of Metalloproteinase-1; D019714:Tissue Inhibitor of Metalloproteinases; D019716:Tissue Inhibitor of Metalloproteinase-2; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9